These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 23228121)
1. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Saponaro F; Faggiano A; Grimaldi F; Borretta G; Brandi ML; Minisola S; Frasoldati A; Papini E; Scillitani A; Banti C; Del Prete M; Vescini F; Gianotti L; Cavalli L; Romagnoli E; Colao A; Cetani F; Marcocci C Clin Endocrinol (Oxf); 2013 Jul; 79(1):20-6. PubMed ID: 23228121 [TBL] [Abstract][Full Text] [Related]
2. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564 [TBL] [Abstract][Full Text] [Related]
3. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108 [TBL] [Abstract][Full Text] [Related]
4. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106 [TBL] [Abstract][Full Text] [Related]
5. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495 [TBL] [Abstract][Full Text] [Related]
6. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use. Norman J; Lopez J; Politz D Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336 [TBL] [Abstract][Full Text] [Related]
7. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery]. Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266 [TBL] [Abstract][Full Text] [Related]
8. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118 [TBL] [Abstract][Full Text] [Related]
9. Cinacalcet for the treatment of primary hyperparathyroidism. Sajid-Crockett S; Singer FR; Hershman JM Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354 [TBL] [Abstract][Full Text] [Related]
10. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783 [TBL] [Abstract][Full Text] [Related]
12. The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Schwarz P; Body JJ; Cáp J; Hofbauer LC; Farouk M; Gessl A; Kuhn JM; Marcocci C; Mattin C; Muñoz Torres M; Payer J; Van De Ven A; Yavropoulou M; Selby P Eur J Endocrinol; 2014 Dec; 171(6):727-35. PubMed ID: 25240499 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study. Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534 [TBL] [Abstract][Full Text] [Related]
14. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339 [TBL] [Abstract][Full Text] [Related]
15. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527 [TBL] [Abstract][Full Text] [Related]
16. Cinacalcet for the treatment of primary hyperparathyroidism. Dillon ML; Frazee LA Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675 [TBL] [Abstract][Full Text] [Related]